JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $4 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Benitec Biopharma (NASDAQ:BNTC) and maintained a $4 price target.
June 26, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Benitec Biopharma (NASDAQ:BNTC) and maintained a $4 price target.
The reiteration of the Market Outperform rating and maintenance of the $4 price target by JMP Securities analyst Silvan Tuerkcan indicates a positive outlook for Benitec Biopharma's stock in the short term. This news is important for investors as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100